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Redox signaling and oxidative stress are associated with tissue ﬁbrosis and aging. Aging is recognized as
a major risk factor for ﬁbrotic diseases involving multiple organ systems, including that of the lung. A
number of oxidant generating enzymes are upregulated while antioxidant defenses are deﬁcient with
aging and cellular senescence, leading to redox imbalance and oxidative stress. However, the precise
mechanisms by which redox signaling and oxidative stress contribute to the pathogenesis of lung ﬁbrosis
are not well understood. Tissue repair is a highly regulated process that involves the interactions of
several cell types, including epithelial cells, ﬁbroblasts and inﬂammatory cells. Fibrosis may develop
when these interactions are dysregulated with the acquisition of pro-ﬁbrotic cellular phenotypes. In this
review, we explore the roles of redox mechanisms that promote and perpetuate ﬁbrosis in the context of
cellular senescence and aging.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Tissue repair is an evolutionally conserved and tightly regu-
lated process that aims to reinstate tissue integrity and functional
capacity of the affected organ. When this process is uncontrolled,
ﬁbrotic repair with attendant loss of organ function may occur.
Fibrosis is excessive accumulation of extracellular matrix (ECM),
due to sustained mesenchymal activation and impaired epithelial
regeneration with varying degrees of inﬂammation. Fibrosis canaccess article under the CC BY-NC
n of Pulmonary, Allergy, and
ngham, 429 Tinsley-Harrison
2180, USA.
nickal).affect diverse organs such as lung, liver, kidney and skin [1]. In-
cidence and prevalence of pathological ﬁbrosis increase with ad-
vancing age. Aging is an independent risk factor for ﬁbrotic dis-
orders [2–8]. However, the mechanistic links between aging and
ﬁbrosis are not well understood [9].
Both aging and ﬁbrosis are associated with redox imbalance
and oxidative stress [10,11]. Redox imbalance/oxidative stress oc-
cur when there is increased production and inefﬁcient scavenging
of reactive oxygen species (ROS) [12]. There is convincing evidence
of increased oxidative stress in ﬁbrotic disorders [13,14], although
precise roles of oxidative stress in the pathogenesis of ﬁbrosis have
not been well-deﬁned [15–17]. Similarly, while there is debate
about the casual role of ROS in aging, there is compelling evidence
that aging is associated with oxidative stress [18]. Can redox-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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this review, we evaluate and discuss the currently available evi-
dence linking oxidative stress and redox mechanisms to age-re-
lated ﬁbrosis.2. Fibrosis is a disease of aging
Aging is a gradual decline in the functional capacity of an or-
ganism predisposing to death [19]. IPF is a disease of aging [9,20],
with increasing incidence and prevalence in human subjects over
the age of 50 years [2,4,21,22]. Additionally, older individuals with
IPF have signiﬁcantly diminished survival [23,24]. Individuals with
progeria syndromes are also at higher risk of ﬁbrotic disorders
[25,26]. Recent studies indicate that shortened telomere length is a
risk factor for IPF [27], and IPF is the most common disorder in
telomere dysfunction syndromes [28]. The risk of liver ﬁbrosis
with chronic viral infections and alcohol exposure also increase
with aging [29]. Increasing age is associated with renal glomer-
ulosclerosis and cardiac ﬁbrosis [5,7]. These studies suggest that
ﬁbrosis involving diverse organ systems may represent a degen-
erative disorder of advancing age. The reasons why older in-
dividuals are prone to ﬁbrosis are still not clear. It is possible that
the altered redox balance with aging skew the cascade of normal
tissue repair responses towards ﬁbrosis.3. Redox mechanisms in ﬁbrosis
Molecular oxygen is used by aerobic organisms to harness en-
ergy from oxidation of energy-rich compounds as a part of normal
metabolism. During this process of oxidative phosphorylation,
highly reactive and partially reduced ROS that include hydrogen
peroxide (H2O2), superoxide anion (O2 ∙), and hydroxyl radical
(OH∙) may be generated [12]. These ROS can damage cellular bio-
molecules such as lipids, protein, and DNA. Excessive exposure to
ROS induces oxidative stress and results in apoptosis, senescence
and/or genetic mutations [30]. To combat increases in ROS, anti-
oxidant systems [glutathione (GSH), catalase, superoxide dis-
mutase (SOD2), nuclear factor erythroid-2 (Nrf-2)] have evolvedFibroblasts
T
M1 M2
EMT Senescence
H2O2
SOD1
N
TGF-β1
Epithelium
Macrophages
Fig. 1. Cell-speciﬁc phenotypes and fates in ﬁbrotic repair Impaired reepithelialization
transition (EMT), and/or senescence. Transforming growth factor-β1 (TGF-β1), a critical
primary cells that secrete and remodel the extracellular matrix (ECM). Myoﬁbroblasts m
production. Reactive oxygen species in form of hydrogen peroxide (H2O2) and hypoch
epithelial injury. Superoxide dismutase-1 (SOD1)-catalyzed H2O2 production mediates tra
pro-ﬁbrotic cellular phenotypes through paracrine effects.[31]. Organisms have also developed purposeful ROS-producing
enzymes (e.g., NADPH oxidases and myeloperoxidases) that par-
ticipate in host defense functions and in cellular signaling [12]. The
apparent contradictory roles of ROS as essential regulators of cel-
lular function vs. cytotoxic mediators are, at least in part, attri-
butable to their concentrations and cellular compartmentalization
[12]. Additionally, these biomolecules can function in a contextual
and antagonistically pleiotropic manner in aging [32,33].
Tissue repair is an orchestrated process that involves recruit-
ment, proliferation, differentiation, deactivation, and apoptosis of
different cell types [34]. Cellular senescence is one of the hall-
marks of aging [19] and can profoundly inﬂuence the tissue repair
process [35]. Fibroblast senescence may restrict the proliferation
of ﬁbroblasts and promote resolution of ﬁbrosis [35,36]. In con-
trast, senescence of epithelial cells can result in diminished ca-
pacity of the regeneration [37,38], and persistent senescence of
ﬁbroblasts can result in impaired clearance due its decreased
apoptosis susceptibility in age-related lung ﬁbrosis [39,40]. Cel-
lular senescence has been associated with increased oxidative
stress [41]. ROS has been shown to regulate the cellular pheno-
types and fates, including differentiation [42,43], apoptosis [44],
migration [45,46], and invasion [47] during tissue repair. There is
growing evidence of a pathological role of redox imbalance and
oxidative stress in ﬁbrotic repair [39,48]. It is plausible that redox
imbalance associated with aging alters redox signaling during
tissue repair, thus, predisposing to non-resolving ﬁbrosis.4. Cell-speciﬁc phenotypes/fates in ﬁbrotic repair
Dysregulated tissue repair may ensure as a result of intrinsic
changes in speciﬁc cell population or due to dysregulated cell-cell
communication. Cellular phenotypes/fates that are consistently
observed in ﬁbrotic repair include: [1] impaired epithelial re-
generation with enhanced apoptosis susceptibility; [2] accumula-
tion of mesenchymal cells with an apoptosis resistant phenotype;
and [3] chronic low-grade inﬂammation and features of im-
munosenescence. Here, we will discuss how redox dysregulation
contributes to these cellular phenotypes and fates associated with
age-related ﬁbrosis (Fig. 1).Myofibroblasts
ECM
GF-β1
Epithelial apoptosis
H2O2
H2O2
H2O2
OX4
H2O2
Neutrophils
HOCl
in ﬁbrotic repair may occur as a result of apoptosis, epithelial-to-mesenchymal
pro-ﬁbrotic cytokine, mediates differentiation of ﬁbroblasts to myoﬁbroblasts, the
ay induce epithelial cell death through NADPH oxidase 4 (NOX4)-dependent H2O2
lorous acid (HOCl) generated by neutrophils and macrophages may contribute to
nsition of M1 macrophages to M2 macrophages, which secrete TGF-β1 and promote
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The alveolar epithelial lining of the lung is covered by type I
pneumocytes (95% of surface area) and type II pneumocytes
(5% of surface lining). Alveolar epithelial cells (AECs) are the
primary site of injury and thought to trigger/initiate the ﬁbrotic
response [49]. While type II AECs proliferate and differentiate to
type I AECs in response to injury, AECs in ﬁbrotic repair appear
prone to undergo apoptosis [50,51] and/or senescence [52,53].
AECs secrete several growth factors/cytokines, such TGF-β1 [54],
platelet-derived growth factor (PDGF) [55], endothelin-1 [56],
angiotensin II [57], and connective tissue growth factor (CTGF)
[58]; these cytokines can directly and indirectly mediate pro-ﬁ-
brotic activation of mesenchymal cells. Apoptosis of AECs has been
shown to initiate ﬁbrosis [49,59,60], and secreted factor(s) from
senescent epithelial cells can induce myoﬁbroblast differentiation
in-vitro [53]. Epithelial cells may potentially undergo phenotypic
transitions to mesenchymal-like cells and contribute to ﬁbrogen-
esis, most likely through secreted mediators [61–63]. Thus, AECs
are not just targets but active participants in the ﬁbrogenic
process.
Mitochondrial ROS has been implicated in pathophysiological
process of many age-related degenerative diseases [64]. The epi-
thelial cell damage seen in IPF is associated with increased mi-
tochondrial ROS [65]. Smoking, a known risk factor for IPF, can
induce epithelial cell senescence in lung by increasing mitochon-
drial ROS [66]. Mitochondrial ROS has also been shown to be cri-
tical for hypoxia-induced alveolar epithelial-mesenchymal transi-
tion [67]. TGF-β1, a key pro-ﬁbrotic cytokine [68,69], has been
shown to induce apoptosis as well as epithelial mesenchymal
transition (EMT) in lung epithelial cells [62,70,71]. ROS plays an
important role in TGF-β1-induced EMT and H2O2 mimics effects of
TGF-β1 in epithelial cells [72]. TGF-β1 has been shown to induce
senescence in lung epithelial cells by upregulation of mitochon-
drial ROS [73].
Mitochondria show signatures of oxidative damage and large
number of mutations with advancing age [74,75]. AECs from IPF
lungs show accumulation of dysfunctional mitochondria [76].
Persistent mtDNA damage can activate intrinsic apoptotic death
pathway due to the collapse in mitochondrial membrane potential
[77,78]. AECs in IPF lung show evidence of mitochondrial dys-
function characterized by low expression of PTEN-induced puta-
tive kinase 1(PINK1) protein [76], a key protective mechanism by
promoting mitophagy in response to oxidative stress [79,80]. Ex-
pression of PINK1 is signiﬁcantly diminished in the aging murine
lung and may contribute to mitochondrial dysfunction; type II
AECs isolated from PINK-deﬁcient mice demonstrate mitochon-
drial dysfunction and are more susceptible to apoptosis [76]. An-
other mitochondrial protein, ROS modulator 1 (Romo1) which is
highly expressed in AECs of IPF lung, mediates apoptosis in re-
sponse to oxidative stress [81]. Romo1 expression is increased
with replicative senescence [82]. These studies suggest that aging
could increase the susceptibility of AECs to oxidative stress, at least
in part, due to deﬁciency of PINK1 and increased expression of
Romo1 and, thus, promote ﬁbrotic repair following injury.
AECs express high levels of caveolin-1, a primary structural
protein of caveolae in plasma membranes, which regulates signal
transduction by its scaffolding properties [83,84]. In several cell
types, caveolin-1 expression increases with aging [85,86]. Pre-
mature senescence is induced by oxidative stress, and this effect is
at least in part mediated by caveolin-1 sequestration of sirtuin-1
and inhibition of its activity [87]. Loss of caveolin-1 limits pre-
mature stress-induced senescence in epithelial cells and protects
from bleomycin-induced ﬁbrosis [88]; whether increased levels of
caveolin-1 in senescent AECs contributes to age-related lung ﬁ-
brosis remains to be determined.Duox1 and Duox2, members of the family of NADPH oxidase
(NOX) enzymes, are expressed in airway epithelia and contribute
to H2O2 release is response to different stimuli [89,90]; however,
their role(s) in ﬁbrosis is not known. Another NOX family member,
NOX4 has been implicated in injury-induced epithelial cell death
and bleomycin-induced ﬁbrosis [91]. Role of NADPH oxidases in
epithelial senescence or aging has not been elucidated. Further
studies are required to determine the precise roles of NOX en-
zymes in epithelial senescence and ﬁbrosis. Nuclear factor, ery-
throid-derived 2, like 2 (Nrf2) is a redox-sensitive transcription
factor that is involved in the activation of antioxidant response
elements (ARE) and induction of antioxidant/defense genes in-
cluding glutathione-S-transferase (GST), NADP(H): quinone oxi-
doreductase 1 (NQO1), thioredoxin, and glutathione peroxidase
(GPx). AECs isolated from Nrf2-deﬁcient mice are prone to oxi-
dant-induced cell death and impaired proliferation [92]; mice with
deﬁcient Nrf2 have increased ﬁbrosis in response to bleomycin
lung injury [93]. Nrf2 activity declines with aging [94–96]. Im-
paired Nrf-2 activation in lung ﬁbroblasts has been shown to
contribute to persistent ﬁbrosis in aged mice [39]; however, the
precise role of Nrf2 signaling in AECs senescence or age-related
ﬁbrosis has not been explored.
Glutathione (GSH), an antioxidant tripeptide, is present in the
epithelial lining ﬂuid of the normal lower respiratory tract [97].
Epithelial lung ﬂuid of IPF patients contains lower levels of GSH,
suggesting increased susceptibility to oxidant-induced epithelial
damage [97,98].
TGF-β1 suppresses gene expression of glutamate cysteine ligase
(GCL), a key enzyme in the biosynthesis of GSH, in alveolar epi-
thelial cells [99,100]. Overexpression of TGF-β1 by intranasal ad-
ministration of an adenovirus expressing constitutively active TGF-
β1 induces lung ﬁbrosis, and is associated with downregulation of
GCL gene expression, decreased GSH levels in bronchoalveolar
lavage, and increased oxidative stress [101]. The adaptive GSH
antioxidant response to cigarette smoking is signiﬁcantly de-
creased in aged mice as compared to young mice [102]. Another
antioxidant defense pathway, the thioredoxin (Trx) system, is ac-
tivated during oxidative stress [103]; although it is strongly ex-
pressed in metaplastic alveolar epithelium, its expression is re-
duced in the ﬁbrotic lesions of IPF subjects [104]. These studies
suggest that aging-induced deﬁciencies in the antioxidant system
may predispose lung epithelial cells to injury and ﬁbrosis. In
contrast, manganese superoxide dismutase (Mn-SOD), a mi-
tochondrial antioxidant enzyme, is highly expressed in type II
pneumocytes and alveolar macrophages in IPF [105]. This response
likely reﬂects ineffective efforts to curb oxidative stress associated
with this age-associated lung disease. Thus, ROS generation from
mitochondria and NOX enzymes can inﬂuence pro-ﬁbrotic AEC
fates such as apoptosis, senescence and EMT (Fig. 2).
4.2. Fibroblasts
Fibroblasts are key effector cells in ﬁbrotic remodeling and
repair [106]. The epithelial injury is followed recruitment and
proliferation of ﬁbroblasts and their differentiation to myoﬁbro-
blasts [107]. Myoﬁbroblast are activated ﬁbroblasts with increased
contractile function, increased ECM production, higher oxidant
production and decreased apoptosis susceptibility [106]. Several
sources of (myo)ﬁbroblast have been proposed and these include
ﬁbroblasts, epithelial cells, endothelial cells, ﬁbrocytes and peri-
cytes [107]. Fibroblastic foci, an aggregation of myoﬁbroblasts, are
a key feature of IPF and the extent of the ﬁbroblastic foci strongly
correlates with impaired pulmonary function and disease pro-
gression [108–110]. While the transient appearance of myoﬁbro-
blasts are essential in normal wound healing, the persistence of
myoﬁbroblasts in the injured tissue is a consistent ﬁnding in
mitoROS
PINK1
Mitophagy
Oxidative
stress
Romo1
Caspase 
activation
ApoptosisGSH
Nrf2
DNA 
damage
NOXes
TGF-β1
TGF-β1 GCL
Senescence
EMT
SIRT1
Cav-1
Fig. 2. Redox alterations in epithelial cells in age-related ﬁbrosis Reactive oxygen
species (ROS) generated from NADPH oxidase enzymes (NOXes) and mitochondria,
along with deﬁcient antioxidant pathways (Nuclear factor erythroid-2 related
factor 2, Nrf2; and glutathione, GSH), results in oxidative stress. Transforming
growth factor-β1 (TGF-β) suppresses gene expression of glutamate cysteine ligase
(GCL), a key enzyme in the biosynthesis of GSH and thus, increases susceptibility to
oxidative damage. Oxidative stress leads to epithelial cell death that has been at-
tributed to a deﬁciency in phosphatase and tensin homolog (PTEN)-induced pu-
tative kinase-1 (PINK1) and increased expression of reactive oxygen species mod-
ulator-1 (Romo1) in mitochondria. Oxidative stress may also induce epithelial se-
nescence through caveolin-1 (Cav-1)-mediated inhibition of sirtuin-1 (SIRT1) ac-
tivity. TGF-β1 induced mitochondrial ROS (mitoROS) has been reported to induce
epithelial-to-mesenchymal transition (EMT). These redox alterations in epithelial
cells promote pro-ﬁbrotic phenotypes such as epithelial apoptosis, EMT and se-
nescence. Red arrows indicate direction of change in age-related ﬁbrosis. (For in-
terpretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
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confers an apoptosis resistant phenotype and contributes to per-
sistent ﬁbrosis in aged mice [39]. Similarly, IPF myoﬁbroblasts ex-
vivo demonstrate a senescent phenotype compared to normal
lung ﬁbroblasts [112], and exhibit apoptosis resistant phenotype
in-vitro [39,51]. In IPF lung, (myo)ﬁbroblasts in ﬁbroblastic foci
show low expression of proliferation marker (Ki67) and higher
expression of the senescent marker, p16 [39]. Senescent ﬁbroblasts
isolated from old mice are apoptosis resistant in-vitro and accu-
mulate following bleomycin injury in-vivo [39,40]. These studies
suggest that IPF may result from the accumulation and activation
of senescent, apoptosis-resistant myoﬁbroblasts.
Mitochondria are the major source of ROS production in eu-
karyotic cells. Mitochondrial ROS production increases with re-
plicative senescence and with aging [113]. TGF-β1 increases mi-
tochondrial ROS which has been shown to induce the expression
of pro-ﬁbrotic genes during myoﬁbroblast differentiation [114].
The matricellular protein CCN1, which is known to induce mi-
tochondrial ROS [115], has been shown to augment TGF-β1 sig-
naling and contribute to ﬁbrogenic responses to lung injury [116].
Interestingly, CCN1 expression increases in replicative senescent
ﬁbroblasts [117], and with aging [118,119]. The in-vivo roles of
mitochondrial ROS in development and/or progression of ﬁbrosis
require further study.
Peroxisomes are small single membrane, self-replicating orga-
nelles that contain enzymes for β-oxidation of fatty acids and
catalase for H2O2 detoxiﬁcation [120]. Compromised peroxisomal
function can lead to increased cellular ROS and induce pro-ﬁbrotic
responses by activation of TGF-β1 signaling [121]. Senescent lung
ﬁbroblasts are associated with decreased peroxisomal catalase
activity and increased ROS production [122]. Hypocatalasemic,individuals with reduced cellular catalase levels, experience pre-
mature onset of age-associated diseases such as type-2 diabetes
and macular degeneration [123,124]. It remains to be determined
whether compromised peroxisomal function with aging results in
reduced catalase levels, oxidative stress and susceptibility to
ﬁbrosis.
Caveolin-1 expression is decreased in myoﬁbroblasts in IPF
[125], and in response to TGF-β1 [126]. Cav-1 negatively regulates
NOX-derived ROS by altering enzymatic activity, post-tran-
scriptionally by direct binding of NOX2 and NOX5 and tran-
scriptionally by inhibiting NF-kB-dependent NOX2 and NOX4 ex-
pression [127], suggesting one mechanism for increased expres-
sion of NOXes in IPF. However, caveolin-1 expression increases
with replicative senescence in ﬁbroblasts [86] in association with
increased expression of NOX4 [128].
NOX4 mediates myoﬁbroblast differentiation through the
generation of H2O2, and this redox signaling pathway is required
for ﬁbrogenic responses to injury [43]. NOX4 expression is in-
creased in different tissues with aging [129,130], and with cellular
senescence in association with epigenetic changes [128]. NOX4
expression is increased in IPF ﬁbroblasts and is required for con-
stitutive expression of their pro-ﬁbrotic phenotype [131]. NOX4
knockdown or pharmacological inhibition of its activity in aged
mice restores the capacity for ﬁbrosis resolution [39].
Nrf2 is a key transcriptional activator of antioxidant genes and
maintains redox balance [132,133]. Nrf2 has been shown to protect
against pulmonary ﬁbrosis in murine models [93,134]. IPF myoﬁ-
broblasts express low levels of Nrf2 in comparison to control ﬁ-
broblasts, and sulforaphane (an Nrf2 activator) induces dediffer-
entiation of myoﬁbroblasts isolated from IPF patients [135]. Nrf2
may induce paradoxical ampliﬁcation of ROS through the stimu-
lation of transcription Kruppel-like factor 9 (Klf9) which regulates
a number of redox-modulating enzymes [209]. Apoptosis of
myoﬁbroblasts is critical for resolution of ﬁbrosis [51], and se-
nescent ﬁbroblasts are resistant to apoptosis [39,40,86]. Nrf2 re-
sponse to oxidative stress is impaired in senescent ﬁbroblasts in
comparison to non-senescent ﬁbroblasts [39]. The ability to induce
Nrf2 in ﬁbroblasts isolated from young mice was found to be cri-
tical for apoptosis susceptibility [39]. Altered redox homeostasis
resulting from elevated expression of NOX4 and a diminished
ability to induce Nrf2 antioxidant response leads to non-resolving
ﬁbrosis in aged mice [39]. Further studies are required to de-
termine whether Nrf2 activation is a beneﬁcial therapeutic strat-
egy for age-related ﬁbrosis.
Altered interactions between epithelial cells and mesenchymal
cells can promote pro-ﬁbrotic environment [53,136,137]. There is
increased epithelial cell death in areas adjacent to myoﬁbroblastic
foci in the lungs of IPF patients [138]. Myoﬁbroblasts can induce
epithelial cells apoptosis by paracrine H2O2 signaling in an ex-vivo
co-culture system of lung epithelial cells and IPF myoﬁbroblasts
[139]. Senescent ﬁbroblasts generate higher levels of extracellular
H2O2 mediated, at least in part, by NOX4 [39,128]. It is possible
that with aging, senescent ﬁbroblasts produce enhanced H2O2 that
contributes to the oxidative microenvironment in ﬁbrotic dis-
orders. The sources of ROS in (myo)ﬁbroblasts may include mi-
tochondria, NOX enzymes and peroxisomes (Fig. 3).
4.3. Inﬂammatory cells
Although the precise role of inﬂammation in ﬁbrosis is debated
[140,141], there is clear evidence for chronic inﬂammation in ﬁ-
brotic disorders such as IPF. A number of studies suggest presence
of activated inﬂammatory cells such as alveolar macrophages and
neutrophils in IPF lung [142–145]. These phagocytic cells may
contribute to oxidant-mediated epithelial injury [146,147]. In ad-
dition, IPF lung tissues demonstrate the accumulation of activated
NOX4
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Fig. 3. Redox alterations in ﬁbroblasts in age-related ﬁbrosis: NADPH oxidase 4
(NOX4) and mitochondrial ROS (mitoROS) have been implicated in myoﬁbroblast
differentiation. Peroxisomal dysfunction and/or a deﬁciency in catalase may ex-
acerbate oxidative stress. Caveolin-1 (Cav-1), a negative regulator of NOX enzymes,
is decreased in myoﬁbroblasts. Transforming growth factor-β1 (TGF-β1) and cy-
steine-rich-61(CYR61)/CCN family member-1 (CCN1) cooperatively induces the
oxidative stress in ﬁbroblasts. Deﬁcient antioxidant mechanisms such as nuclear
factor erythroid-2 related factor 2 (Nrf2) leads to sustained oxidative stress. The
sustained oxidative stress due to decreased antioxidant activity and increased
oxidant production promotes pro-ﬁbrotic mesenchymal phenotype. Red arrows
indicate direction of change in age-related ﬁbrosis. (For interpretation of the re-
ferences to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
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Fig. 4. Redox alterations in macrophages in age-related ﬁbrosis: Deﬁcient oxidative
burst in aged macrophages may increase susceptibility to viral infections, which
results in sustained inﬂammatory response and epithelial damage. Hydrogen per-
oxide (H2O2), catalyzed by superoxide dismutase-1 (SOD1), has been reported to
regulate M1 to M2 polarization of macrophages. M2 macrophages secrete pro-ﬁ-
brotic factors such as transforming growth factor-β1 (TGF-β1) and Rac1-dependent
H2O2 secretion, which further promote pro-ﬁbrotic phenotypes in epithelial cells
and ﬁbroblasts. Red arrows indicate direction of change in age-related ﬁbrosis. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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licular dendritic cells [148–151]. “Inﬂammaging” is systemic low
grade inﬂammation associated with aging, accompanied by di-
minished immunocompetence due to imunosenescence, compro-
mised immunoregulatory mechanisms and/or increased auto-
immunity [152,153]. Loss of immune regulation with inﬂamma-
ging may explain, in part, autoantibodies associated with IPF [154–
158].
Neutrophils, the most abundant of circulating granulocytes, are
part of innate immune system and are recruited during tissue
injury. Neutrophils contain NADPH oxidases and myeloperoxidases
that generate large quantities of oxidants, O2. , H2O2, and hypo-
chlorous acid (HOCl) [159,160]. Neutrophil accumulation and ac-
tivation have been shown to correlate with disease progression in
IPF [147,161,162]. The contribution of aging to neutrophil super-
oxide production is less clear, with marked variability depending
on the stimulus; some studies suggest that neutrophils have re-
duced oxidative burst capacity with aging [163–166], and other
studies suggest normal or increased superoxide production
[167,168]. Neutrophils isolated from elderly subjects produce
lower levels of superoxide in response to N-formyl-methionyl-
leucyl-phenylalanine at early time-points, while this effect is
sustained over a longer period; this may be related to a failure in
the regulatory pathway to de-activate neutrophils in aged in-
dividuals [169]. These studies suggest that counter-regulatory
mechanisms or intrinsic cellular dysfunction (such as senescence)
may result in sustained ROS production, epithelial injury and
ﬁbrosis.
Macrophages may mediate both pro- and anti-ﬁbrotic effects
depending on its phenotype during the evolution of tissue injury
repair. There are two distinct phenotypes of macrophages: M1
polarized macrophages are responsible for initial inﬂammatory
response and clearing of pathogens, whereas M2 polarized mac-
rophages are resolution of inﬂammation, ﬁghting parasitic infec-
tions and tissue remodeling [170,171]. Macrophages can promote
ﬁbrosis through both direct and indirect actions [172]. Macro-
phages, especially M2 polarized, can activate myoﬁbroblasts by
secreting pro-ﬁbrotic mediators such as TGF-β1 [173]. Arginase,
expressed in M2 macrophages, can promote the production ofcollagen substrates such as proline and glutamate [173,174].
Superoxide is converted to H2O2, either spontaneously, or by
superoxide dismutases (SODs). Mitochondrial Cu, Zn-SOD ex-
pression is increased in alveolar macrophages of asbestosis pa-
tients and can promote ﬁbrosis by augmentation of H2O2 pro-
duction [175]. Recently, Cu, Zn-SOD (SOD1), has been reported to
mediate the M2 polarization of macrophages in redox-dependent
manner to promote ﬁbrotic tissue repair [176,177]. Macrophage
polarization can be affected by aging [178]. The M2 response to
interleukin-4 (an M2 inducer) is diminished in aged macrophages,
which suggests that diminished M2 responses during aging may
contribute to impaired resolution of inﬂammation [178]. Further
studies are required to investigate the effect of aging on macro-
phage polarization and redox signaling in age-related ﬁbrosis.
Alveolar macrophages isolated from bronchoalveolar lavage of
IPF patients produce signiﬁcantly elevated levels of ROS [179].
High levels of myeloperoxidases in alveolar epithelial lining ﬂuid is
associated with increased epithelial injury and rapid decline of IPF
patients [147]. In animal model of asbestos-induced ﬁbrosis, al-
veolar macrophages produce H2O2, derived from complex III of the
mitochondrial electron transport chain. Rac1 is a member of the
Rho family of small GTPases which regulates actin polymerization
and ROS generation. Rac1 null mice when asbestos have less oxi-
dative stress and are protected from pulmonary ﬁbrosis [180].
Intra-tracheal exogenous catalase prevents pulmonary ﬁbrosis
prevented mice form asbestos induced ﬁbrosis [180]. These studies
suggest that macrophages in IPF actively produce ROS and growth
factors which can not only lead to epithelial cell damage and
mesenchymal activation (Fig. 4). During aging, there is increase in
population of alveolar macrophages [181]. Older mice also show
elevated levels of pro-inﬂammatory cytokines and a resident po-
pulation of highly activated pulmonary macrophages [182]. Para-
doxically, macrophages from aged mice and rats show diminished
capacity of superoxide production [183–185]. As a consequence of
reduced respiratory burst, elderly subjects may be more prone to
opportunistic bacterial and viral infections [186,187]. Human
herpes virus (HHV) and Epstein–Barr virus (EBV) have been im-
plicated in the pathogenesis of IPF [188]. Macrophages following
herpes virus infection generate increased ROS, which may mediate
both antiviral effects and contribute to tissue injury [189–191].
HHV is found in macrophages of IPF lung [192], suggesting that the
virus may evade killing by macrophages. Although there is a
A. Kurundkar, V.J. Thannickal / Redox Biology 9 (2016) 67–7672decline in phagocytic functions of macrophages with aging, a
sustained chronic, low level of inﬂammation due inﬂammatory
cytokine production by macrophages (known as inﬂammaging)
may contribute to persistent ﬁbrosis with aging [193]. The role of
immunosenescence and inﬂammaging in age-related lung ﬁbrosis
deserves further study.5. Potential of redox modulatory therapy in IPF
Aging is accompanied by increase in oxidative modiﬁcations of
cellular as well as extracellular proteins and these oxidized pro-
teins contribute to pathophysiology of age-related diseases
[194,195]. Oxidized proteins undergo covalent crosslinking such as
dityrosine and disulﬁde formation and result in the accumulation
of non-degradable insoluble protein aggregates [196,197]. Fibrosis
is characterized by excessive accumulation of insoluble matrix
proteins and crosslinking of matrix proteins can hinder the re-
solution of ﬁbrosis [198]. Our lab has shown that TGF-β1 induces
oxidative dityrosine-dependent cross-linking of matrix proteins in
lung ﬁbroblasts [199] and that the levels of protein tyrosine oxi-
dation are signiﬁcantly elevated in plasma of patients with inter-
stitial lung diseases [200]. It is possible that the non-degradation
and progressive accumulation of insoluble oxidized proteins can
contribute to persistent ﬁbrosis with aging. Further studies are
necessary to understand the precise role of these chemical mod-
iﬁcations in age-related ﬁbrosis.
Current studies suggest that the homeostatic balance between
oxidants and antioxidants is altered in age-related lung ﬁbrosis
and contribute to its pathogenesis. Restoration of redox imbalance
using exogenous redox modulatory agents could be an effective
therapeutic strategy in age-related lung ﬁbrosis. GSH levels are
essential for an optimal antioxidant defense against oxidative
stress. N-acetylcysteine (NAC), a precursor of GSH synthesis, is a
scavenger of ROS and has been shown to ameliorate ﬁbrosis in
various animal models [201,202]. NAC has been shown to improve
redox imbalance in IPF [203]; however, its therapeutic efﬁcacy is
variable with most of studies indicating minimal effect [204,205].
Genetic factors such as speciﬁc gene polymorphisms may explain
the variable response to NAC therapy in IPF patients, and suggest
personalized approaches to more effective treatment of IPF [206].
GKT137831, a speciﬁc NOX1/4 inhibitor developed by Genkyotex
(Geneva, Switzerland), has been shown to partially reverse per-
sistent ﬁbrosis in aged mice [39]. However, its therapeutic efﬁcacy
has not been evaluated in IPF patients. Resveratrol, a plant-derived
antioxidant stilbenoid, attenuates oxidative stress and ﬁbrosis in
animal models [207,208], although clinical trials have not been
conducted. Similarly, studies of Nrf2 activators for IPF are lacking.
Thus, clinical studies of a number of potentially effective redox-
modulatory therapies may be anticipated in the near future. In
addition to the identiﬁcation of critical targets and development of
safe, selective compounds for clinical testing, personalized ap-
proaches to study design are likely to produce the best results.6. Conclusion
Normal tissue repair mandates a well-organized temporal ex-
ecution of reparative functions and interactions between different
cell types. Imbalance in redox regulatory mechanisms associated
with aging can result from deﬁcient activity of antioxidant me-
chanisms or elevated generation of ROS. Age-related increases in
ROS generation may be related to mitochondrial dysfunction and/
or higher expression and activity of NOX enzymes. As highlighted
in this review, the redox imbalance with aging can lead to pro-
found alterations in cellular phenotypes and cell-cell interactionsthat amplify ﬁbrotic responses. Strategies that reinstate redox
balance in age-related lung ﬁbrosis may prove to be ther-
apeutically more effective.Acknowledgements
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